Cristina González-Mingot

Dr. Cristina González-Mingot

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 September 2012 in Journal of Neurochemistry
Verified
Journal Article
Closed access
PDF file
HGHugo Gonzalo
Hugo Gonzalo
LBLluís Brieva
Lluís Brieva
FTFranz Tatzber
Franz Tatzber
MFMariona Jove Font
Mariona Jove Font
DCDaniel Cacabelos
Daniel Cacabelos
MPManuel Portero-Otin
Manuel Portero-Otin

25 November 2010 in Journal of Neurology
Verified
Journal Article
Closed access
PDF file
FMFrancisco Javier Miana-Mena
Francisco Javier Miana-Mena
CGCristina González-Mingot
Cristina González-Mingot
PLPilar Larrodé
Pilar Larrodé
MMMaría Jesús Muñoz
María Jesús Muñoz
SOSara Olivan
Sara Olivan
JGJosé Joaquín García García
José Joaquín García García

31 March 2011 in Journal of Bioenergetics and Biomembranes
Verified
Journal Article
Closed access
PDF file
FMFrancisco Javier Miana-Mena
Francisco Javier Miana-Mena
EPEduardo Piedrafita
Eduardo Piedrafita
CGCristina González-Mingot
Cristina González-Mingot
PLPilar Larrodé
Pilar Larrodé
MMMaría Jesús Muñoz
María Jesús Muñoz
JGJosé Joaquín García García
José Joaquín García García

25 June 2013 in European Journal of Neurology
Verified
Journal Article
Closed access
PDF file
Francisco PurroyFrancisco Purroy
Francisco Purroy
ISI. Suárez‐Luis
I. Suárez‐Luis
GMG. Mauri‐Capdevila
G. Mauri‐Capdevila
SCSerafí Cambray
Serafí Cambray
JFJ. Farré
J. Farré
IBI. Benabdelhak
I. Benabdelhak

1 November 2016 in Journal of Neuroimmunology
Verified
Journal Article
Closed access
MGMar Guasp
Mar Guasp
NSNuria Sola-Valls
Nuria Sola-Valls
EMEugenia Martínez-Hernández
Eugenia Martínez-Hernández
MGM Pilar Gil
M Pilar Gil
CGCristina González-Mingot
Cristina González-Mingot
HAHelena Ariño
Helena Ariño

15 September 2022 in The Journal of Headache and Pain
Verified
Journal Article
Open access
PDF file
CGCristina González-Mingot
Cristina González-Mingot
AGAnna Gil-Sánchez
Anna Gil-Sánchez
MCMarc Canudes-Solans
Marc Canudes-Solans
SPSilvia Peralta-Moncusi
Silvia Peralta-Moncusi
MSMaria José Solana-Moga
Maria José Solana-Moga
LBLuis Brieva-Ruiz
Luis Brieva-Ruiz
To study the impact of chronic migraine (CM) on the cognition and quality of life (QoL) of patients in the interictal period, and to analyse the degree of reversibility of any observed alterations following the use of preventive treatment. CM is a highly disabling disease, and migraineurs often have associated comorbidities, such as subjective memory problems, that are involved in the development of cognitive impairment. Our hypotheses are that patients suffering from chronic migraine experience objective cognitive alterations that are not only due to the pain that they suffer or their current emotional state. Furthermore, preventive treatment should be capable of reversing, or at least reducing, the impact of CM on the cognition and QoL of migraineurs. The cognition and QoL of 50 control subjects and 46 patients with CM were assessed using a battery of tests, prior to the use of preventive treatment based on botulinum toxin or oral drugs and after 3 months of this treatment. Compared with controls, patients with CM had lower scores on the assessment of cognitive performance (Rey-Osterrieth Complex Figure test [ROCF] (p<0.05), Trail Making Test [TMT] B) (p < 0.05) and QoL (p < 0.05). Three months after the use of preventive treatment, improvement was observed in all cognitive parameters (p < 0.05) and QoL (p < 0.05), except the ROCF copy task (p = 0.79). No statistically significant differences were observed when these outcomes were compared based on treatment. This study confirms poor cognitive performance that is not explained by migraine pain itself, as it occurs in the interictal period, irrespective of the patient’s emotional status. Our findings show that these effects are reversible in some cases with preventive treatment of CM, reaffirming the important impact of this condition on the QoL of these patients, and the need to establish preventive treatment guidelines.